Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 18.45 as of 2026-10-06T17:17:11.920Z.
Consensus retrieved: 2026-10-06T13:34:08.842Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:17:11.920Z.
Quote observation: 2026-10-06T17:15:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 65ba41422cb3637e97ef4c6419befa8fb59be581510cab4be329864b9dfe44ec
Forward PE Ratio (18.45) = Dated Quote Price ($99.90) / Consensus Forward EPS ($5.41)
FORWARD PE RATIO
18.45
SECTOR MEDIAN · HEALTHCARE
19.77
median of 182 covered companies
CURRENT VS SECTOR MEDIAN
-6.65%
vs the sector median at left
Lantheus Holdings, Inc.
Market Cap
$6.50B
Forward PE Ratio
18.45
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | $6.50B | 18.45 |
| Immunovant, Inc. (IMVT)vs › | $6.52B | N/A |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 19.86 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.53B | N/A |
| Chemed Corporation (CHE)vs › | $6.66B | 19.98 |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.20B | N/A |
| Alkermes plc (ALKS)vs › | $6.95B | N/A |
| GRAIL Inc. (GRAL)vs › | $6.03B | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.93B | 31.80 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.93B | N/A |
Trailing P/E
24.1
reported TTM EPS
Forward P/E
18.4
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $5.41 implies +30.7% EPS growth vs the reported trailing $4.14.
At the dated quote price of $99.90, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $5.41 | $5.06 – $5.84 | 4 | 18.5x |
| 2027-12-31 | $6.40 | $5.81 – $7.04 | 6 | 15.6x |
| 2028-12-31 | $7.87 | $5.97 – $10.27 | 3 | 12.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
